This is a key loan, which will help finance Transgene's new clinical developments for the treatment of infectious diseases, including chronic hepatitis B, virus-induced cancers such as HPV (human papilloma virus) and tuberculosis.
European Commissioner for Research, Science and Innovation Carlos Moedas commented: "This deal under InnovFin's IDFF facility, once again shows the EU's determination to tackle major public health problems. We hope that this loan will help to improve the treatment and quality of life of people affected by these diseases."
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.32 (c)||1.22%||14 979|